Basel Medical Group Ltd closes $7.98 million registered direct offering of units

Offering structure: Company sold 6,000,000 units at US$1.33 per unit, each consisting of one Ordinary Share and one Common Warrant; no Pre-Funded Warrants were issued.

Gross and net proceeds: Offering produced US$7.98 million in gross proceeds and an estimated US$7.28 million in net proceeds before commissions and offering expenses.

Use of proceeds: Net proceeds are designated for general working capital, mergers and acquisitions, and other general corporate purposes.

Warrant terms: Each Common Warrant has a five-year term, an exercise price of US$1.463 (110% of the offering price), and includes a zero-cash-exercise option that would result in the issuance of up to 6,000,000 additional Ordinary Shares without additional cash consideration to the Company.

Share count impact: Ordinary Shares outstanding increased from 1,582,111 immediately before to 7,582,111 immediately after the closing, with 6,000,000 Common Warrants also outstanding.

Lock-up restrictions: The Company and its executive officers, directors, and pre-offering 5%+ shareholders entered into 180-day lock-up agreements with the Placement Agent, including restrictions on additional financings during the lock-up period.

Placement agent and counsel: Cathay Securities, Inc. acted as exclusive placement agent; Sichenzia Ross Ference Carmel LLP advised the Company on U.S. securities law matters, and Hunter Taubman Fischer & Li LLC advised the placement agent.